With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

2.

Herpes virus-based vaccine shows promise in targeting tumors without side effects

3.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

4.

Liver cancer survival rates reflect income disparities

5.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot